1. Home
  2. ICMB vs GANX Comparison

ICMB vs GANX Comparison

Compare ICMB & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICMB
  • GANX
  • Stock Information
  • Founded
  • ICMB 2012
  • GANX 2017
  • Country
  • ICMB United States
  • GANX United States
  • Employees
  • ICMB N/A
  • GANX N/A
  • Industry
  • ICMB Finance: Consumer Services
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ICMB Finance
  • GANX Health Care
  • Exchange
  • ICMB Nasdaq
  • GANX Nasdaq
  • Market Cap
  • ICMB 46.5M
  • GANX 41.9M
  • IPO Year
  • ICMB N/A
  • GANX 2021
  • Fundamental
  • Price
  • ICMB $3.22
  • GANX $1.54
  • Analyst Decision
  • ICMB
  • GANX Strong Buy
  • Analyst Count
  • ICMB 0
  • GANX 5
  • Target Price
  • ICMB N/A
  • GANX $7.60
  • AVG Volume (30 Days)
  • ICMB 30.6K
  • GANX 204.1K
  • Earning Date
  • ICMB 02-10-2025
  • GANX 11-14-2024
  • Dividend Yield
  • ICMB 14.91%
  • GANX N/A
  • EPS Growth
  • ICMB N/A
  • GANX N/A
  • EPS
  • ICMB 0.29
  • GANX N/A
  • Revenue
  • ICMB $24,827,371.00
  • GANX N/A
  • Revenue This Year
  • ICMB N/A
  • GANX N/A
  • Revenue Next Year
  • ICMB N/A
  • GANX N/A
  • P/E Ratio
  • ICMB $11.04
  • GANX N/A
  • Revenue Growth
  • ICMB N/A
  • GANX N/A
  • 52 Week Low
  • ICMB $2.91
  • GANX $0.89
  • 52 Week High
  • ICMB $3.96
  • GANX $5.33
  • Technical
  • Relative Strength Index (RSI)
  • ICMB 57.37
  • GANX 39.69
  • Support Level
  • ICMB $3.11
  • GANX $1.59
  • Resistance Level
  • ICMB $3.24
  • GANX $1.70
  • Average True Range (ATR)
  • ICMB 0.07
  • GANX 0.15
  • MACD
  • ICMB 0.00
  • GANX -0.00
  • Stochastic Oscillator
  • ICMB 80.00
  • GANX 10.15

About ICMB Investcorp Credit Management BDC Inc.

Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Share on Social Networks: